Varied functions of immune checkpoints during cancer metastasis Ali SafarzadehMohsen AlizadehNicola Silvestris Review Open access 09 September 2020 Pages: 569 - 588
Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer H. AdderleyF. H. BlackhallC. R. Lindsay Review Open access 11 September 2020 Pages: 589 - 595
A systematic scoping review on natural killer cell function in colorectal cancer Fiona S. W. ReidNatasha EgoroffStephen R. Smith Review 11 September 2020 Pages: 597 - 606
Pembrolizumab and atezolizumab in triple-negative breast cancer Dorota Kwapisz Review 05 October 2020 Pages: 607 - 617
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives Jingjing QuQuanhui MeiJianying Zhou Review Open access 06 October 2020 Pages: 619 - 631
Anti-tumor and immune modulating activity of T cell induced tumor-targeting effectors (TITE) Archana ThakurSri Vidya KondadasulaLawrence G. Lum Original Article 31 August 2020 Pages: 633 - 656
Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab Toshiki KijimaHina YamamotoYasuhisa Fujii Original Article 02 September 2020 Pages: 657 - 665
Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma Huayu YangLejia SunYilei Mao Original Article 02 September 2020 Pages: 667 - 677
Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies Alexandra FrelauXavier Palard-NovelloAntoine Girard Original Article 03 September 2020 Pages: 679 - 687
Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies Wei ZhangSeong-Min LimJun-O Jin Original Article 09 September 2020 Pages: 689 - 700
Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study Qinchuan WangYuanqing YeXifeng Wu Original Article Open access 09 September 2020 Pages: 701 - 712
Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase Qi XiongZiwei HuangYi Hu Original Article 10 September 2020 Pages: 713 - 720
Next-generation humanized patient-derived xenograft mouse model for pre-clinical antibody studies in neuroblastoma Rosa NguyenAnand G. PatelMichael A. Dyer Original Article 11 September 2020 Pages: 721 - 732
Reviving up dendritic cells can run cancer immune wheel in non-small cell lung cancer: a prospective two-arm study Asmaa M. ZahranHelal F. HettaAmal Rayan Original Article 12 September 2020 Pages: 733 - 742
A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC) J. ChandraW. P. WooSandro V. Porceddu Original Article 12 September 2020 Pages: 743 - 753
Flow cytometric analysis of circulating endothelial cells and endothelial progenitor cells in pediatric solid tumors: prognostic impact on treatment response and survival Heba Abdel Razik SayedHelal F. HettaAsmaa M. Zahran Original Article 18 September 2020 Pages: 755 - 761
Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors Kyriakos P. PapadopoulosNehal LakhaniJudy S. Wang Original Article Open access 28 September 2020 Pages: 763 - 772
Systematic analysis of immune-related genes based on a combination of multiple databases to build a diagnostic and a prognostic risk model for hepatocellular carcinoma Di-guang WenXiao-ping ZhaoZuo-jin Liu Original Article 28 September 2020 Pages: 773 - 786
Anti-leukemia effect associated with down-regulated CD47 and up-regulated calreticulin by stimulated macrophages in co-culture Eman M. HassanGilbert C. WalkerShan Zou Original Article 29 September 2020 Pages: 787 - 801
Differential gene expression of tumor-infiltrating CD33+ myeloid cells in advanced- versus early-stage colorectal cancer Salman M. ToorRowaida Z. TahaEyad Elkord Original Article Open access 30 September 2020 Pages: 803 - 815
Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells leading to resistance to antibody-dependent cellular cytotoxicity Mariko NishieEiji SuzukiMasakazu Toi Original Article 30 September 2020 Pages: 817 - 830
High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient Elena AnghileriNatalia Di IanniSerena Pellegatta Original Article 03 November 2020 Pages: 831 - 842
PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures Kathryn M. AppletonAshley K. ElrodTeresa M. DesRochers Original Article 25 January 2021 Pages: 843 - 856
Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study Haiping JiangYulong ZhengNong Xu Clinical Trial Report Open access 17 October 2020 Pages: 857 - 868
Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas Daniel J. LandsburgAlexa KoikeGabriel C. Caponetti Research Report 28 August 2020 Pages: 869 - 874